Myzomib is an antineoplastic (anti-cancer) medication that belongs to the class of proteasome inhibitors. It is primarily used for the treatment of multiple myeloma and mantle cell lymphoma. By disrupting cellular processes, it helps to prevent cancer cells from growing and multiplying.

Uses

Multiple Myeloma: Myzomib is often used as a first-line treatment in combination with other drugs such as dexamethasone or lenalidomide.

Mantle Cell Lymphoma (MCL): It is approved for the treatment of MCL in patients who have received at least one prior therapy.

Myzomib inhibits the 26S proteasome, a protein complex involved in breaking down unneeded or damaged proteins. By inhibiting the proteasome, Myzomib induces apoptosis (programmed cell death) in cancer cells, disrupting their survival mechanisms.